Because previous studies have reported that the AKT pathway is the most critical pathway in renal cell carcinoma, an AKT inhibitor (MK2206) was used to investigate whether CVB exerts antitumour effects mainly through the AKT signalling pathway. This evidence concerns the gene AKT1 and hereditary clear cell renal cell carcinoma.